drugset / Trial / NCT01090323
Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The safety, tolerability, effects on liver iron concentration and pharmacokinetics of ICL670 is studied in sickle cell disease patients with transfusional hemosiderosis.
Timeline
- Start
- 2004-07
- Primary completion
- 2009-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferasirox | Unknown | 5 mg/kg | Oral |
| Subject | Deferasirox | Unknown | 40 mg/kg | Oral |